Blocking a key enzyme in Alzheimer's patients' immune cells shifted them from inflammatory to protective | Research

The takeaway

Inhibiting FAAH in monocytes from Alzheimer's patients reduced pro-inflammatory cytokines and shifted macrophages toward an anti-inflammatory, neuroprotective state.

Alzheimer's researchers, immunologists, anyone following endocannabinoid-based therapeutics

FAAH inhibition reduced pro-inflammatory and increased anti-inflammatory cytokines in AD monocytes

What the researchers found

AD patients had lower CB1 and CB2 expression on B-lymphocytes and monocytes, with higher FAAH levels in monocytes. Blocking FAAH in these cells reduced TNF-alpha, IL-6, and IL-12 while increasing anti-inflammatory IL-10, and shifted macrophages toward a more protective phenotype. Monocytic CB2 and FAAH levels correlated with clinical scores.

Why it matters

If peripheral immune cells contribute to Alzheimer's progression, and their inflammatory behavior can be modulated through the endocannabinoid system, this opens a novel therapeutic approach targeting immune cells rather than brain cells directly.

The numbers in context

CB1 and CB2 lower in AD B-lymphocytes; CB2 lower and FAAH higher in AD monocytes; FAAH blockade reduced TNF-alpha, IL-6, IL-12 and increased IL-10; T-lymphocytes and NK cells showed no changes

How the study worked

Comparison of endocannabinoid system markers on immune cells from AD patients versus healthy controls, followed by in vitro pharmacological FAAH inhibition experiments on patient-derived monocytes and macrophages.

What this study cannot tell us

In vitro manipulation may not translate to in vivo effects. Cross-sectional design cannot establish causation. Small sample size typical of such studies. Effects on disease progression were not measured.

How to read the evidence

In vitro study using cells from AD patients, providing mechanistic insight but not clinical evidence

When this study was published

Published in 2021. FAAH inhibitors for neurodegenerative diseases remain in early research stages.

The bigger picture

This supports a growing understanding that Alzheimer's involves peripheral immune dysregulation, and that the endocannabinoid system could be leveraged to shift immune cells from harmful to protective roles.

Questions still open

Would systemic FAAH inhibition reduce neuroinflammation in AD patients? Could peripheral immune markers be used to monitor AD progression? Are there FAAH inhibitors suitable for clinical trials in AD?

Common questions

Could targeting the endocannabinoid system help with Alzheimer's?

This study found that blocking FAAH in immune cells from AD patients reduced inflammation and shifted them toward a protective state. This suggests a potential therapeutic approach, though clinical testing is needed.

What is FAAH and why does it matter?

FAAH is an enzyme that breaks down endocannabinoids. It was found at higher levels in AD patients' monocytes. Blocking it enhanced anti-inflammatory endocannabinoid signaling, which could help create a more neuroprotective environment.

Read the original research

Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients.

Biomolecules, 11(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Chiurchiù, Valerio; Scipioni, Lucia; Arosio, Beatrice; Mari, Daniela; Oddi, Sergio; Maccarrone, Mauro. (2021). Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients.. Biomolecules, 11(4). https://doi.org/10.3390/biom11040502